BEGIN:VCALENDAR VERSION:2.0 X-WR-CALNAME:biospain2025 X-WR-CALDESC:Event Calendar METHOD:PUBLISH CALSCALE:GREGORIAN PRODID:-//Sched.com BIOSPAIN 2026//EN X-WR-TIMEZONE:UTC BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T070000Z DTEND:20260929T073000Z SUMMARY:Opening Remarks DESCRIPTION:Inaugural speeches by the President of the Association and authorities CATEGORIES:CEREMONY LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:3dcaa5bce02066e90c255054c8edab80 URL:http://biospain2025.sched.com/event/3dcaa5bce02066e90c255054c8edab80 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T081500Z DTEND:20260929T090000Z SUMMARY:Inside Spanish Biotech VC Playbooks: What Moves the Investment Needle DESCRIPTION:Want to tilt the odds in your favor on the roadshow? Hear it straight from the source: Spain’s top biotech VCs will unveil their investment playbooks—how they judge scientific risk\, vet team credentials and experience\, assess development plans\, and prioritise therapeutic areas. Each investor gets a brisk\, 9-minute spotlight to explain what truly moves the needle. Walk away with a sharper sense of how opportunities are valued and what to emphasize in your pitch. CATEGORIES:REVERSE PITCH PRESENTATION LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:14748ef882ecfc8899127b24e26af75f URL:http://biospain2025.sched.com/event/14748ef882ecfc8899127b24e26af75f END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T081500Z DTEND:20260929T090000Z SUMMARY:Biologics as Strategic Capability: Europe's Production Base in a New Security Era DESCRIPTION:The ongoing challenges at Europe's borders and beyond\, the lingering effects of COVID-19\, and the shifting landscape of biological threats have fundamentally reshaped the way Europe must approach its biologic sector. Vaccines\, therapeutics\, and diagnostics are no longer just healthcare solutions\, they are essential strategic assets. Europe's ability to produce these tools quickly\, at scale\, and on home soil has become a cornerstone of both defense and crisis resilience.\n\nThis session brings together key leaders from Europe’s defense\, health security\, and intelligence sectors to tackle a crucial question: What infrastructure\, coordination\, procurement strategies\, and alliance frameworks does Europe need to ensure its biologics production meets the demands of future crises? By leveraging lessons from recent events and the strategic insights currently driving EU and national plans\, panelists will evaluate Europe’s manufacturing readiness\, the strategic role of stockpiles\, the integration of intelligence in preparedness\, and the necessary public-private collaboration to turn strategic goals into operational capabilities.\nDG DEFISDG HERAMinisterio de Defensa: ManufNATO Innovation Fund - David Ordóñez- esta persona la habíais propuesto vosotros - podrías contactar a ver si ella o alguien más podría tener interés en participar?UK - estamos en contacto con el consulado de Barcelona a ver qué recomendaciones nos pueden darHIPRA - Carlota Gómez De la Hoz - Corp. Affairs & Sustain. Exec. Director\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:0628d1613b3184aaf7d889f1d04d2014 URL:http://biospain2025.sched.com/event/0628d1613b3184aaf7d889f1d04d2014 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T090000Z DTEND:20260929T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:6d129d6cb3d8c4f51b71aadbb82020c1 URL:http://biospain2025.sched.com/event/6d129d6cb3d8c4f51b71aadbb82020c1 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T090000Z DTEND:20260929T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:702ad04a69646acc3d68c2cb375f1fdd URL:http://biospain2025.sched.com/event/702ad04a69646acc3d68c2cb375f1fdd END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T090000Z DTEND:20260929T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:d29a165c91dfaef4723cc6965124e77d URL:http://biospain2025.sched.com/event/d29a165c91dfaef4723cc6965124e77d END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T090000Z DTEND:20260929T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:f741637cbc5c6d1b017c8c69dcd05ab5 URL:http://biospain2025.sched.com/event/f741637cbc5c6d1b017c8c69dcd05ab5 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T093000Z DTEND:20260929T100000Z SUMMARY:Progress and challenges of advanced therapies for rare diseases DESCRIPTION:Dr. Bueren leads the Biomedical Innovation Unit at CIEMAT and also conducts research at CIBERER and the Jiménez Díaz Foundation Health Research Institute. Throughout his career\, he has made decisive contributions to the development of new gene and cell therapies targeting rare and hereditary diseases\, driving the translation of research from the laboratory to clinical practice.\n\nInternationally recognized for his scientific contributions and leadership in the field of gene therapy\, he has also served as president of the European Society for Gene and Cell Therapy\, promoting the advancement and accessibility of these innovative therapies for patients.\n\nAt BIOSPAIN\, he will will share an updated perspective on the advances transforming the treatment of rare diseases\, as well as the scientific\, regulatory\, and access challenges that still need to be overcome to ensure these therapies reach all patients who need them. CATEGORIES:KEYNOTE SPEAKER LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:25b33adc5512b62eec60e77ed4c48317 URL:http://biospain2025.sched.com/event/25b33adc5512b62eec60e77ed4c48317 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T093000Z DTEND:20260929T101500Z SUMMARY:Choosing the Basque Country to grow your business in life sciences and health – discover the reasons DESCRIPTION:Since the launch of the BioBasque strategy in 2002\, Euskadi has invested in consolidating an innovation ecosystem which supports the growth of the health and life sciences industry. Under the overarching strategy of clusters as models for growth of sophisticated sectors\, a sustained institutional support and the public-private collaboration have leveraged the development of a growing industry currently comprised of more than 300 companies (including specialised suppliers) that account for more than 8% of the direct employment in the Basque Country. The industry is also supported and accompanied by the Basque Network of Science\, Technology and Innovation\, composed of a rich tissue of organisations (Universities\, BERC\, Cooperativa Research Centres-CIC\, Technology Centres gathered in BRTA\, and Health Research Institutes among others) which provides skilled capabilities and contribute to generate deeptech start ups.\n\n\nSince 2015\, the industry has experienced very significant growth in the number of companies (60%)\, and particularly in terms of turnover (187%) and employment (151%). Most of this growth has been endogenous\; even today\, the generation of innovative and tech companies in the health/life sciences area remains strong (first in Spain\, in number of companies per capita). However\, in the recent past\, the region is becoming an attractive location for companies\, and people\, that decide to relocate or establish operations and grow their business here.\n\n\nThis session will explore the factors that make the Basque Country attractive\, from different points of view including international companies\, investors\, and researchers\, as well as the Basque Health Cluster and the health public administration.\n\n Eikonoklastes Therapeu cs\, TBC \;\n\n\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:3c3c43167cd61193452f31474fcb0241 URL:http://biospain2025.sched.com/event/3c3c43167cd61193452f31474fcb0241 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T093000Z DTEND:20260929T101500Z SUMMARY:What’s the Secret Sauce Behind a Successful Spin-off? DESCRIPTION:Key success factors behind high-performing spin-offs\, including team\, science\, funding strategy and execution. What to take into account in the early stages to move fast\, de-risk projects and build strong foundations for growth. Insights and lessons learned from real cases and different stakeholder perspectives.\n\nAgnés Arbat (Oxolife) - Spanish biotech founderGustavo Fuster (Hoffmann Eitle) - IP lawyerEtienne Drouet (IQVIA) – CRO (Regulatory and Clinical)Marcos Simón (CIC Biomagune) – Head of TTO\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:853fc45544a85fe732757b46c7fe8133 URL:http://biospain2025.sched.com/event/853fc45544a85fe732757b46c7fe8133 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T093000Z DTEND:20260929T101500Z SUMMARY:Startup pitch presentations: Bioeconomy DESCRIPTION:Meet innovative startups that are seeking funding to address some of the key challenges of our society. From global warming to the challenge of feeding more than 8 billion people or the need to manage waste and byproducts\, biotechnology is offering creative solutions and alternatives.\n\nStart-ups will have the opportunity to present their business plans to a panel of investors. Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2026.\n\n\nPresenting companies:\n\n\nBioceanics \;– Clara Bartra\, CEOBioPredX \;– Helena García Cebollada\, CEOCalfix \;– Pablo Montequín\, CEOGenbioma \;– Josune Ayo\, CEOHeuristik \;– Antxon Caballero\, CEONUCAPS \;– Mariano Oto\, CEO\n\n\n CATEGORIES:STARTUP PITCH PRESENTATIONS LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:ad7a7c42fde843c854efda07f3b25d8b URL:http://biospain2025.sched.com/event/ad7a7c42fde843c854efda07f3b25d8b END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T101500Z DTEND:20260929T110000Z SUMMARY:Beyond Discovery: How AI\, Advanced Therapeutics and Clinical Evidence Are Reshaping Biotech Innovation DESCRIPTION:The biotechnology sector is entering a new era in which innovation is no longer driven by scientific discovery alone. The increasing convergence of artificial intelligence\, advanced therapeutic approaches\, and data-driven clinical decision-making is fundamentally transforming the way new healthcare solutions are conceived\, developed\, validated\, and ultimately delivered to patients. As scientific and technological capabilities continue to evolve\, collaboration across disciplines has become essential to accelerate innovation\, reduce development timelines\, and improve healthcare outcomes.\nFrom the earliest stages of target identification and drug discovery to the generation of clinical evidence that supports regulatory approval\, market access\, and patient care\, biotechnology companies are embracing new technologies that are reshaping every step of the innovation pathway. Artificial intelligence is enabling researchers to analyse complex biological data with unprecedented speed and precision\, novel therapeutic strategies are opening new possibilities for treating diseases previously considered undruggable\, and real-world data is becoming an indispensable tool for demonstrating the value and effectiveness of healthcare innovations beyond the clinical trial setting.\nThis session will bring together three innovative companies representing complementary areas of this evolving biotechnology ecosystem. Their experiences will illustrate how cutting-edge science\, digital technologies\, and clinical evidence generation can work together to create a more integrated\, efficient\, and patient-centred model of innovation. Through their different perspectives\, the discussion will explore how multidisciplinary collaboration is becoming one of the key drivers of competitiveness within the global biotech industry.\nBeyond showcasing technological advances\, the panel will also address some of the major challenges facing biotechnology companies today\, including access to high-quality data\, regulatory adaptation to emerging technologies\, talent attraction\, investment\, and the importance of building collaborative innovation ecosystems capable of supporting companies from early-stage research through to market adoption.\nThe discussion will also provide an opportunity to reflect on Europe's position within an increasingly competitive global landscape. As biotechnology becomes more digital\, interconnected\, and data-intensive\, strengthening collaboration between startups\, healthcare providers\, research organisations\, technology developers\, investors\, and public institutions will be critical to ensuring that innovation reaches patients faster and more effectively.\nThis session is designed for biotech entrepreneurs\, pharmaceutical and medtech companies\, researchers\, investors\, healthcare professionals\, and innovation policymakers interested in understanding how the next generation of biotechnology will be built through the integration of artificial intelligence\, advanced therapeutic innovation\, and clinical evidence.\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:440495cca443a6cb7d929de649f7aa89 URL:http://biospain2025.sched.com/event/440495cca443a6cb7d929de649f7aa89 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T101500Z DTEND:20260929T110000Z SUMMARY:Europe’s Biotech Moment: What the Biotech Act Must Deliver DESCRIPTION:The year 2025 has been marked by the Biotech Act\, the proposed Regulation through which the European Commission aims to establish a comprehensive regulatory framework to foster investment\, innovation\, and competitiveness in the biotechnology sector at a pivotal moment for Europe's strategic autonomy.\nAgainst this backdrop\, this session will explore how the Biotech Act represents an opportunity to strengthen the competitiveness of the Spanish biotechnology sector. In particular\, the discussion will focus on some of the proposals expected to have the greatest impact on the industry\, including Strategic Projects\, financing pilots\, the extension of the Supplementary Protection Certificate (SPC)\, and measures to accelerate clinical trials.\n\nEstado ponentes:Moderador: Ion Arocena\, Director General de AseBio\nJavier Padilla Bernáldez\, Ministry of Health\, Secretary of State - CONFIRMADOCristina Nadal Sanmartin\, Executive Director of Policy\, MSD in Spain - CONFIRMADOSandra Gallina\, Directorate-General for Health and Food Safety\, European Commission – mandada invitación \n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:11c72bbe204e76491261097f7cdcc47d URL:http://biospain2025.sched.com/event/11c72bbe204e76491261097f7cdcc47d END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T101500Z DTEND:20260929T111500Z SUMMARY:Startup Pitch Presentations: Oncology DESCRIPTION:Companies seeking funding to develop treatments in neurology and oncology will present their companies and pitch their business opportunity.\n\nAttendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.\nAbility Pharmaceuticals\, SA  \;– \;Carles Domènech\, CEOInnoup Farma Kinsy\, S.l.  \;–  \;Elisa Longás\, Chief Business OfficerLabsinlove S.L. - Cristina Aguilera\, CEOLifesome Therapeutics\, S.L.  \;– Ana Bouchet\, CEOMIMO BIOSCIENCES  \;– \;Jessika Valero Gonzalez\,. Business Development DirectorNuage Therapeutics  \;– \;Andri Leonidou\, Head Of Bi And Corporate AffairsOncomatryx Biopharma SA \; \;– \;Teresa Rodriguez-Carmona Garcia\, Business Development AssociatePeptomyc\, S.l.  \;– \;Jesús Martín García\, CEOTrimerbody Pharma  \;– \; \;Marta Compte Grau\, R&D Director\n CATEGORIES:STARTUP PITCH PRESENTATIONS LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:37e16ab09c8b3644e77843b5fe8ab3e4 URL:http://biospain2025.sched.com/event/37e16ab09c8b3644e77843b5fe8ab3e4 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T110000Z DTEND:20260929T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:9f0fddf21d3031c74da229ce1cdc43f2 URL:http://biospain2025.sched.com/event/9f0fddf21d3031c74da229ce1cdc43f2 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T110000Z DTEND:20260929T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:ae92e8f1b9ea21865dcb93932d9115b6 URL:http://biospain2025.sched.com/event/ae92e8f1b9ea21865dcb93932d9115b6 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T110000Z DTEND:20260929T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:f8d834d9f8a86e27f153fb6af934a6f5 URL:http://biospain2025.sched.com/event/f8d834d9f8a86e27f153fb6af934a6f5 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T111500Z DTEND:20260929T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:09f83c566a64d8e430cd71edc01cbdcc URL:http://biospain2025.sched.com/event/09f83c566a64d8e430cd71edc01cbdcc END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T123000Z DTEND:20260929T131500Z SUMMARY:Boosting biotechnology development accelerators DESCRIPTION:The Biotech Act will establish the first comprehensive framework to promote biotechnology as a strategic sector for the European Union’s competitiveness\, public health\, sustainability\, and technological autonomy. The law aims to position Europe in the global competition with the United States and China in this strategically important field.\nAbout fostering biotechnology startup companies in the health sector\, the Biotech Act outlines the structural conditions and mechanisms needed to accelerate innovation and improve the translation of research into market applications\, so that such initiatives may be recognized by the Commission as “high impact health biotechnology strategic projects”.\nThe Biotech Act advocates for achieving critical mass through clusters - not hundreds of small biotechnology hubs scattered everywhere - but rather half a dozen large “super-clusters” capable of attracting substantial investment and offering strong\, competitive capacities in innovation\, manufacturing\, and infrastructure.\n\n-Lilly\, pendiente ponente CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:b75d276e234acd016b561f09b9a93d88 URL:http://biospain2025.sched.com/event/b75d276e234acd016b561f09b9a93d88 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T123000Z DTEND:20260929T131500Z SUMMARY:From Zero to GMP. Built to Scale DESCRIPTION:Ponentes:\nDámaso Molero\nReprsentante de Sartorius\, \nReopresentante de un cliente \nRepresentante de ingeniería CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:a15a10c5436d2cfeac140504d122ec5a URL:http://biospain2025.sched.com/event/a15a10c5436d2cfeac140504d122ec5a END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T123000Z DTEND:20260929T131500Z SUMMARY:Joint Opportunities for the UK and Spain through Horizon Europe Collaborations. DESCRIPTION:As the Guest Nation of BIOSPAIN 2026\, the United Kingdom takes centre stage in this high-level round table exploring how UK–Spain collaboration can drive innovation\, competitiveness and growth across the life sciences sector through Horizon Europe.\n\n Bringing together leading British and Spanish voices from across biotech\, research\, innovation and public-sector collaboration\, this session will examine the strategic value of stronger bilateral partnerships within the Horizon Europe framework. Speakers will discuss how organisations in both countries can work together more effectively in R&D\, translational science\, health innovation\, industrial biotech and international consortia-building.\n\nThe discussion will highlight practical pathways for collaboration between UK and Spanish stakeholders\, showcase examples of successful partnership models\, and explore how both countries can leverage their complementary scientific strengths\, innovation ecosystems and shared ambitions to unlock new opportunities in European funding and cross-border innovation.\n\n The round table will offer attendees a timely opportunity to hear directly from experts and decision-makers on the future of UK–Spain cooperation in biotech and the wider life sciences landscape\, while celebrating the UK’s special role at BIOSPAIN 2026.\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:2de8b53d77fc5f1356ce6831a221e787 URL:http://biospain2025.sched.com/event/2de8b53d77fc5f1356ce6831a221e787 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T123000Z DTEND:20260929T131500Z SUMMARY:Spanish biotech spin-offs and their integration into the global ecosystem: reaching out and attracting EU\, US and Asia players. DESCRIPTION:Spanish biotech spin-offs are stepping onto the global stage like nimble launchpads of innovation\, pulling in investors and partners from Europe\, the US and Asia. Rooted in world-class science yet built for translation\, they marry academic brilliance with entrepreneurial grit — and with sharper international branding\, smoother regulatory pathways and bolder cross-border alliances\, they can turn local discoveries into scalable\, globe-spanning solutions. CATEGORIES:ROUND TABLE DISCUSSION LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:0fb16e355a54c7b8d9d7aea6acd1f1f4 URL:http://biospain2025.sched.com/event/0fb16e355a54c7b8d9d7aea6acd1f1f4 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T131500Z DTEND:20260929T140000Z SUMMARY:Advanced therapies and next-gen biotech platforms to deliver global health impact DESCRIPTION:Advanced Therapies and Next-Gen Biotech Platforms to Deliver Global Health Impact\nGiven the relative strength of the Basque Country in industrial biotechnology capabilities—particularly in advanced manufacturing\, regenerative medicine\, and translational research—this proposal envisions a coherent set of 2–3 interconnected BIOSPAIN 2026 sessions exploring advanced therapies and next-generation biotech platforms from complementary perspectives. Rather than a single discussion\, the aim is to reflect the breadth and maturity of the regional ecosystem by distributing expertise across multiple formats\, including thematic panels and moderated discussions.\nThese sessions would collectively examine how scientific innovation\, industrial scale-up\, and clinical translation converge to enable global impact in advanced therapies. While each session would address a distinct angle—from platform technologies and manufacturing infrastructure to translational science and clinical application—they would be designed to offer a unified narrative around the Basque Country’s role as a European hub for advanced biomedicine.\nAcross the proposed sessions\, participation would include leading voices from biotechnology companies\, industrial-scale manufacturing organizations\, and academic and translational research institutions:\nThe session provides a review of platform technologies and genome engineering\, industrialization and manufacturing of gene and cell therapies\, and translational research and clinical integration\, depending on final program design.\nOverall\, this proposal aims to showcase the Basque Country’s distinctive positioning at the intersection of industrial capability\, scientific excellence\, and translational innovation\, illustrating how regional strengths can be leveraged to drive global health impact in advanced therapies through coordinated\, multi-stakeholder dialogue.\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:06e0fababd70eca4a70f27494d9368aa URL:http://biospain2025.sched.com/event/06e0fababd70eca4a70f27494d9368aa END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T131500Z DTEND:20260929T140000Z SUMMARY:Bizkaia\, an entrepreneurial region: building instruments to boost strategic sectors DESCRIPTION:Bizkaia has developed its own model for promoting strategic sectors\, based\, on the one hand\, on the territory's capacity to design and activate advanced tax instruments\, and on the other hand\, on the creation of new financing vehicles that combine private contributions or facilitate access to cutting-edge enabling technologies. \n\nIn this round table\, representatives from the Bizkaia Provincial Treasury\, Seed Capital Bizkaia\, BEAZ\, and Lank will share how the territory has built specific tools to accelerate innovation and generate new opportunities in sectors such as biotechnology\, combining tax incentives\, specialized public investment\, and future-oriented technological strategies like BIQAIN.\n\nOscar Ugarte (director general de Seed Capital Bizkaia) *provisional \n Valentín García (director de Innovación de Lantik) *provisional\n Antonio Perez (Director General de Hacienda de Bizkaia) \n\n\n\n\n\n\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:ec3e15f6b6b69621e5b7396ce93a09b1 URL:http://biospain2025.sched.com/event/ec3e15f6b6b69621e5b7396ce93a09b1 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T131500Z DTEND:20260929T134500Z SUMMARY:Startup Pitch Presentations: Devices & Diagnostics DESCRIPTION:Build high-impact investor pitches that translate medical-device and in vitro diagnostics innovation into clear financial potential and patient-outcome narratives investors can’t ignore.\n\nAttendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027. \nDebios Diagnostics — Joan Grasas\, Ceo\nManina Medtech — Mónica\, Rodríguez de la Vega Otazo\, CEO\nOpportunity Health — Germán Alejandro Sánchez Martín\, CEO\nOptec4Life — \;Francesc Paris Huguet\, CEO CATEGORIES:STARTUP PITCH PRESENTATIONS LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:8edf0a4f11ea7a40d6249e714896ae3e URL:http://biospain2025.sched.com/event/8edf0a4f11ea7a40d6249e714896ae3e END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T140000Z DTEND:20260929T144500Z SUMMARY:AI and quantum computing in drug discovery: transforming molecular design and therapeutic development DESCRIPTION:Quantum technologies are rapidly evolving from theoretical promise to practical tools across biomedicine and biotechnology. Early applications in drug discovery\, molecular simulation\, quantum enhanced imaging\, and secure data infrastructures are already underway\, supported by hybrid quantum–classical approaches and pioneering industrial collaborations. This panel will bring together experts from quantum computing\, biotechnology\, diagnostics\, and cybersecurity to explore near term opportunities and realistic pathways for adoption.Participants will gain insights into emerging use cases\, regulatory considerations\, and strategic actions enabling biotech and health organizations to prepare for the quantum decade ahead.Introduction: Why Quantum for Biotech Now? (5 min)Block 1 – Quantum Computing in Biomedicine: Molecules\, Models and Precision Medicine (20 min)Block 2 – Quantum Sensing\, Imaging and Diagnostics: The Next Frontier (20 min)Block 3 – Quantum Biotech Industrial Collaborations and Biomanufacturing (20 min)\n1. Mujer TBC\, Multiverse Computing2. Javier Aizpurua\, Scientific director\, BasQ-Basque Quantum Strategy TBC CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:36ab9663a64aea4380469fc8c5156583 URL:http://biospain2025.sched.com/event/36ab9663a64aea4380469fc8c5156583 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T140000Z DTEND:20260929T144500Z SUMMARY:Engineering the Materials of Life DESCRIPTION:Engineered living materials (ELMs) are composed\, either entirely or partly\, of living cells. ELMs entirely composed of living cells are called biological ELMs and they self-assemble via a bottom-up process – e.g. synthetic morphogenesis for organoids’ production. ELMs only partly composed of living cells are called hybrid living materials (HLMs) and are built with a top-down process with integrated polymers or scaffolds. In both cases\, the cellular components extract energy from the environment to form or assemble the material itself\, and to adapt its morphology and function to environmental stimuli. This endows these materials with a combination of properties not present in any non-living material: self-regeneration\, adaptation to environmental clues\, longevity and environmental sustainability. By being alive\, ELMs represent a fundamental change in materials’ production and performance\, enabling new\, better or similar functionalities\, compared to traditional materials but with decreased costs and environmental impact. ELMs have the potential to transform virtually every modern endeavour from healthcare to infrastructures to transportation.\n\nRepresentante de Cocoon?\nRepresentante de Regemat3D?\nRepresentante de BASF CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:00348b1ee7a343557a2c83dcda8288e0 URL:http://biospain2025.sched.com/event/00348b1ee7a343557a2c83dcda8288e0 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T140000Z DTEND:20260929T144500Z SUMMARY:Making ATMPs Sustainable in 2026: What Gets Funded\, Scaled\, and Acquired? DESCRIPTION:Following a market correction\, ATMPs are entering a more selective phase where scientific promise must be matched by clear execution. This session will examine what differentiates companies that get funded\, scaled\, and ultimately acquired. The discussion will focus on investor selection criteria at seed and Series A\, including data thresholds\, platform differentiation\, and capital efficiency. It will also address the role of delivery and manufacturing in enabling—or limiting—scalability. From a pharma perspective\, the panel will highlight what drives partnering and acquisition decisions\, and why many ATMP companies fail to reach that stage. Bringing together investors\, founders\, pharma\, and manufacturing experts\, the session will provide a practical framework to assess ATMP opportunities in today’s environment.\n\nRegulatoria: AEMPS o alguna empresa experta en el tema (ej.: Asphalion o Clarek + Modet). TBCLegislación: un perfil que conozca la legislación y marco europeo (aquí sugeriríamos alguien de Vinces) TBC\n\n\n\n\n5. Legislative perspective: VINCES??? CATEGORIES:ROUND TABLE DISCUSSION LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:d981cb8b37d2109ed29adff686cb2146 URL:http://biospain2025.sched.com/event/d981cb8b37d2109ed29adff686cb2146 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T140000Z DTEND:20260929T144500Z SUMMARY:Women’s health & care as a growing industry DESCRIPTION:Women specificities in healthcare are gaining importance due to the higher socieconomical status in developed countries and insights from research highlighting sex and gender disparities in the development\, prevention and treatment of diseases. As an example\, cardiovascular disease remains the leading cause of death among women in the EU\, yet it is still under-researched\, frequently misdiagnosed\, and often undertreated. Understanding women's health requires moving beyond a "one-size-fits-all" medical model to one that recognizes the profound impact of sex and gender on health outcomes and considers the differential needs in prevention and treatment. In parallel\, there is a growing high-tech market delivering new healthcare products and services specifically designed for women\, the so-called femtech sector\, with innovations specifically designed for women’s wellness or care related to diagnostic devices\, wearable sensors\, etc. This panel will analyze this healthcare paradigm change and the related technological innovations as well as the integration of these aspects into routine clinical workflows by multidisciplinary experts including a cardiologist with expertise in digital health and AI\, pharma and femtech companies.\nRepresentante de Abbvie \;–TBC.Representante de Qassay \;–TBC.\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:c2d667451320374ec5514fda9570a125 URL:http://biospain2025.sched.com/event/c2d667451320374ec5514fda9570a125 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T144500Z DTEND:20260929T153000Z SUMMARY:Advancing Cell & Gene Therapies: Challenges\, Innovation & Market Translation DESCRIPTION:Cell and gene therapies (CGT) have revolutionised the treatment of many conditions and they continue to attract significant levels of investment. Their development faces unique challenges\, ranging from technical complexity\, regulation\, scaling production\, and the requirement of innovative commercialization models. This roundtable will explore how CGT can be effectively translated into innovation that reaches the market\, creates value\, and improves people’s lives. A range of topics will be covered\, with particular emphasis on some key challenges such as response durability\, toxicity management\, targeting of solid tumours\, and the development of robust analytical workflows for functional characterisation\, including approaches such as real-time cytotoxicity assays and multimodal cell profiling.\n\n\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:816a6494b0889fdd28fa0adac090bdbc URL:http://biospain2025.sched.com/event/816a6494b0889fdd28fa0adac090bdbc END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260929T144500Z DTEND:20260929T153000Z SUMMARY:Biotech Act: Accelerating Biotech Scale-Up and Building Competitive Value Chains in Europe DESCRIPTION:Following the publication of the proposed Biotech Act I Regulation\, the European Commission has launched a consultation process for the future Biotech Act II\, which will focus on industrial policy and on building a broad\, forward-looking biotechnology ecosystem.\nIn this session\, organised by AseBio\, we will examine the opportunities presented by Biotech Act II to advance biomanufacturing and biotechnology innovation in Europe\, while also addressing the regulatory\, financing\, and scale-up challenges facing the sector.\n\nEstado ponentes: \;\nModerador: Ion Arocena\, General Director of AseBio\nMiguel Ángel Pavón\, Directorate-General for Industrial Strategy and Small and Medium-sized Enterprises (SMEs)\, Ministry of Industry and Turism – mandada invitaciónMrs Kristin Schreiber\, Director Chemicals\, Bioeconomy and Retail\, DG GROW.F\, European Commission – mandada invitaciónJoerg Lindemann - MD / Site Manager WACKERAna Maria Bravo-Angel\, Director of Public Affairs at IFF - mandada invitación\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:7cb3e37b9eb15a5956006f0dc8085d1a URL:http://biospain2025.sched.com/event/7cb3e37b9eb15a5956006f0dc8085d1a END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T073000Z DTEND:20260930T081500Z SUMMARY:From Strategy to Collective Action: Building Europe's Agri-Food Biotech Ecosystem Together DESCRIPTION:Europe has no shortage of ambitious strategies for biotechnology. The challenge now is implementation.\nDelivering a competitive\, resilient and sustainable European agri-food biotechnology ecosystem will require coordinated action across industry\, startups\, academia\, investors\, farmers\, policymakers and innovation organisations. No single stakeholder can deliver this transformation alone.\nThis roundtable will build on the key insights and recommendations collected by the EU Agri-Food Biotech Alliance from representatives from across the entire value chain—including the European Commission\, EFSA\, industry leaders\, startups\, investors\, research organisations\, farmers\, retailers and ecosystem partners—to identify the priorities and actions needed to accelerate biotechnology adoption in Europe.\nThe discussion will focus on how organisations can work together to reduce fragmentation\, align around common priorities\, launch collaborative initiatives and create greater impact through collective action. The session will conclude with a call for organisations across the value chain to join the effort and help shape a stronger\, more connected European agri-food biotechnology ecosystem.\n\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:84d06c5e44f5babe4034cb1089b7a74b URL:http://biospain2025.sched.com/event/84d06c5e44f5babe4034cb1089b7a74b END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T073000Z DTEND:20260930T081500Z SUMMARY:The Clinical Future of Bioprinting: From biofabrication technologies to next-generation regenerative therapies DESCRIPTION:Bioprinting is rapidly evolving from an emerging laboratory technology into a transformative clinical platform with the potential to redefine regenerative medicine. This roundtable will bring together key European stakeholders from biofabrication\, robotics\, clinical translation and advanced manufacturing to discuss how bioprinting can successfully move from research environments into real-world medical practice.\nThrough complementary perspectives\, the discussion will address the major challenges and opportunities facing the field: unmet clinical needs\, in vivo bioprinting\, robotic-assisted biofabrication\, industrial scalability\, regulatory pathways\, hospital integration and next-generation regenerative therapies. The session aims to provide a realistic and strategic vision of how the clinical future of bioprinting can be built.\nThe roundtable would be moderated by Andrea García Lizarribar (TECNALIA)\, who will guide the discussion around the technological\, clinical and industrial pathways required to accelerate the adoption of biofabrication technologies in healthcare.\nThe proposed panel creates a strong and complementary storyline around the clinical translation of bioprinting technologies:\n\nEnabling technologies and manufacturing platforms → REGEMAT 3DTogether\, the panel balances:\nclinical perspectiveindustrial scalabilityenabling technologiesadvanced therapiesfuture-oriented innovationwhile maintaining a realistic and high-impact discussion on how bioprinting can successfully transition from research laboratories into clinical practice.The session offers a unique opportunity to showcase how European innovation ecosystems are shaping the future of clinically applicable biofabrication technologies. CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:f7b73f9484e66a6aa66022cce843b791 URL:http://biospain2025.sched.com/event/f7b73f9484e66a6aa66022cce843b791 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T081500Z DTEND:20260930T090000Z SUMMARY:Regulating Intelligence: Bringing AI-Powered Medical Devices to the European Market under MDR and the AI Act DESCRIPTION:Artificial intelligence is transforming medical devices\, particularly software-based technologies for early disease detection and personalised healthcare. However\, in 2026 AI-powered medical devices in Europe will operate under a dual regulatory framework shaped by Regulation (EU) 2017/745 (MDR) and the Artificial Intelligence Act\, creating one of the most complex compliance environments globally.\nThis session will bring together a Notified Body representative\, a startup with an AI-based speech analysis platform for early detection of dementia\, Parkinson’s disease and cardiovascular conditions\, and regulatory strategy experts. The panel will provide a multidisciplinary and practice-oriented discussion on how innovative AI solutions can successfully reach the European market.\nKey discussion points include:\nQualification and classification of AI-based software as medical devicesClinical evidence expectations for machine learning systemsLifecycle management of adaptive algorithmsInteraction between MDR and the AI Act requirementsData governance and high-risk AI systemsRegulatory pitfalls and common deficiencies identified by Notified BodiesStrategic considerations for startups scaling internationallyThe discussion will address whether Europe can maintain global competitiveness in digital health while ensuring patient safety and regulatory robustness. By combining regulatory authority perspective\, industry experience and strategic advisory insight\, this session offers a practical roadmap for innovators navigating AI medical device development in Europe. CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:682117bf92f3d2b3d80bad1744ebee27 URL:http://biospain2025.sched.com/event/682117bf92f3d2b3d80bad1744ebee27 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T081500Z DTEND:20260930T084500Z SUMMARY:Startup pitch presentations: Early stage companies DESCRIPTION:Meet early stage companiesseeking seed/series A funding\nAttendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.\n\n\nBackpacked-Antibody platform \; – Izaskun Morillo\, Postdoctoral ResearcherExitium Therapeutics \; – Angélica Figueroa Conde-Valvís\, CSOKorum Diagnostics \; – Carla Ferrero Ruedas\, CEOLumina \; \;– \;Guillem Loren\, CEOPlatelet Biotechnologies S.l. \; \;– \;Andrea Acebes Huerta\, CEO & Cofounder\n CATEGORIES:STARTUP PITCH PRESENTATIONS LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:b7497b37ddd249f2dcb396ec2c8a15aa URL:http://biospain2025.sched.com/event/b7497b37ddd249f2dcb396ec2c8a15aa END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T090000Z DTEND:20260930T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:2d281975de5c257786c8fc142ef902d5 URL:http://biospain2025.sched.com/event/2d281975de5c257786c8fc142ef902d5 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T090000Z DTEND:20260930T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:6d1009640c36caa6128785b480e53ff9 URL:http://biospain2025.sched.com/event/6d1009640c36caa6128785b480e53ff9 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T090000Z DTEND:20260930T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:c0f2138654c90998798f96e2fc5eb578 URL:http://biospain2025.sched.com/event/c0f2138654c90998798f96e2fc5eb578 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T090000Z DTEND:20260930T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:dc1ac79f1fd41617ccb0e1e3e609bb7d URL:http://biospain2025.sched.com/event/dc1ac79f1fd41617ccb0e1e3e609bb7d END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T093000Z DTEND:20260930T101500Z SUMMARY:Fishing in the Atlantic Marine Biotech Innovation Ecosystem: from potential to societal impact DESCRIPTION:Fishing in the Atlantic Marine Biotech Innovation Ecosystem: A Comprehensive Examination of Emerging Scientific and Technological Potential\, Pathways for Development and Commercialization\, Policy and Governance Challenges\, and the Tangible Societal Impacts on Coastal Economies\, Public Health\, Biodiversity Conservation\, and Community Resilience This expanded formulation frames a broad\, multi-dimensional exploration of the Atlantic marine biotechnology and fisheries landscape — tracing how basic research and nascent technologies move through translational development\, entrepreneurship\, and regulatory systems into real-world applications. It highlights interconnected topics such as sustainable resource management\, value-chain innovation (from bioprospecting to bio-based products)\, equity and livelihoods for coastal communities\, environmental and biodiversity considerations\, and measurable benefits to public health\, regional economies\, and social well-being. The emphasis is on understanding not just the scientific potential but also the institutional\, economic\, and societal mechanisms that determine whether innovations deliver meaningful\, equitable impact.\n\nRepresentative of A4F CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:2b5aa4a276b0e86b80f918fd84c1d5dc URL:http://biospain2025.sched.com/event/2b5aa4a276b0e86b80f918fd84c1d5dc END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T093000Z DTEND:20260930T101500Z SUMMARY:From Platform to Patient: Scaling Biotech and Advanced Therapies Through Integrated CDMO Ecosystems DESCRIPTION:As biologics and advanced therapies—including proteins\, antibodies\, and ATMPs—reshape the therapeutic landscape\, the key challenge is no longer only scientific\, but industrial. This roundtable will explore how CDMOs are evolving beyond isolated capabilities into integrated\, platform-driven ecosystems that accelerate development\, reduce risk\, and enable efficient path-to-patient.\n\n\nRather than focusing solely on technologies\, the discussion will highlight how collaboration across specialized players—viral vector developers\, biologics manufacturers\, and fill-finish experts—can create seamless development pathways. The goal is to understand how to connect early innovation with robust\, scalable\, and compliant manufacturing strategies.\nKey Discussion Topics\nPlatforms as enablers: How standardized platforms can reduce timelines and costs\, while balancing the need for flexibility in complex and novel therapies.\n\n \;End-to-end thinking: The importance of integrating drug substance and drug product considerations early to avoid late-stage challenges.\nScaling advanced therapies: Key bottlenecks in moving from clinical to commercial manufacturing\, particularly for ATMPs and viral vectors.\nThe power of proximity: Why close collaboration between CDMO teams and developers is critical to accelerate decision-making\, knowledge transfer\, and execution.Differentiation Angle:\n\nThis session will provide a strategic perspective on how to move from fragmented innovation to coordinated industrial execution—combining platform efficiency with collaboration—to ultimately deliver complex therapies to patients faster and more reliably.\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:cc377a449f58dee8519c4ea5bf4f380a URL:http://biospain2025.sched.com/event/cc377a449f58dee8519c4ea5bf4f380a END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T093000Z DTEND:20260930T101500Z SUMMARY:The Role of Clusters in Fostering the Biotech Ecosystem DESCRIPTION:1. Conselleiro de Educación\, Ciencia\, Universidades y FP (Nota: Este seria nuestro Conselleiro\, es donde esta integrada la Agencia Gallega de Innovación(GAIN))\nRomán Rodríguez González\nMails:\nconselleiro.educacion.ciencia@xunta.gal (Conselleiro de Educación\, Ciencia\, Universidades y FP)\npablo.ferradas.madrinan@xunta.gal (Jefe Gabinete Conselleiro)\ngabinete.educacion.ciencia@xunta.gal (Secretaria Conselleiro)\n2. Conselleiro de Sanidad\nAntonio Gómez Caamaño\nMails:\ngabinete.sanidade@sergas.es (Conselleiro de Sanidad)\nconcepcion.bilbao.golpe@xunta.gal (Jefa Gabinete Conselleiro)\nsecretaria.gabinete@sergas.es (Secretaria Conselleiro)\n\nRegional biotechnology clusters and associations play a vital role in strengthening the biotechnology ecosystem by promoting collaboration among stakeholders\, facilitating knowledge transfer\, and accelerating the scientific and business development of the sector. Their work enhances the competitiveness of biotechnology companies while reinforcing the innovation and growth potential of their respective regions.\n\nThe aim of this session is to examine the role of biotechnology clusters in the development of the sector\, explore how they collaborate with one another\, and identify the key strengths and challenges across different regions\, highlighting both shared priorities and the distinctive characteristics of each regional ecosystem. The discussion will also address the Biotech Act proposal to promote networks of biotechnology clusters as a means of strengthening competitiveness and fostering collaboration across the European biotechnology sector.\n\nPropuesta de Ponentes: \;\n\nModerador: Acesabio o bien AseBio y metemos a Acesabio como ponente?\nIdoia Muñoz\, Directora del BHCRobert Fabregat\, Director general de BiocatJesús Agüero\, Director BiovalZara Pons\, General Manager BIOIBLoli Pereiro\, Manager Bioga\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:2ebae4e2b39c16903f0788adca9da4c2 URL:http://biospain2025.sched.com/event/2ebae4e2b39c16903f0788adca9da4c2 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T093000Z DTEND:20260930T101500Z SUMMARY:Startup Pitch Presentations ATMP DESCRIPTION:Meet innovative companies developing Advanced Therapy Medicinal Products\, which are innovative drugs for human used based on genes\, cells or tissue engineering.\n\nStart-ups will have the opportunity to present their business plans to a panel of investors. Attendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2026. \;\n\nPresenting companies:\n\nAmets Biotechnology  \;– \;Laia Trigueros Motos\, CEOGolden Gate Biotech - Jascha Blobel\, CEO\nMiramoon Pharma \;  \;–  \;Amalia Capilla\,  \;CEO\nNocturna Therapeutics \; \; –  \; Miriam Corredor\, CEOPeaches S.l.  \; \;– \; \; Francesca Sarno\, CSOPopcorn Therapeutics – \; Iker Ausejo Mauleon\,COOTetraneuron SL  \; \;– \;  \;Ángel Lucio Pereira\, CEO\n CATEGORIES:STARTUP PITCH PRESENTATIONS LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:c8bbf20cc322caf05109ca14678437ad URL:http://biospain2025.sched.com/event/c8bbf20cc322caf05109ca14678437ad END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T101500Z DTEND:20260930T110000Z SUMMARY:From Lab to Market: Financing Spain’s Deep-Tech Future through Innvierte & Tech Transfer DESCRIPTION:Spain is doubling down on early-stage innovation with the launch of the Innvierte Deep-Tech & Tech Transfer programme\, led by CDTI Innovación under the Ministry of Science\, Innovation and Universities (MICIU)\, in collaboration with the European Investment Fund. With a total allocation of €353 million targeting early-stage technologies (TRL 2–4)\, this initiative aims to close Spain’s critical funding gap between research and commercialization—unlocking the potential of universities\, research centers\, and spin-offs.\n This round table will explore how public-private co-investment models—such as the recent €30 million commitment into the Montana Children’s Health fund managed by Ship2B Ventures—can catalyze a stronger deep-tech ecosystem. Panelists will discuss the role of institutional capital in de-risking early innovation\, the challenges of tech transfer in Spain\, and how to scale breakthrough science into globally competitive companies.\n Key questions include: How can Spain better align financial instruments with the needs of deep-tech entrepreneurs? What lessons can be drawn from this first Innvierte transaction? And how can investors\, corporates\, and public actors collaborate to accelerate the journey from lab to market?\n The session is designed for investors\, fund managers\, tech transfer offices\, policymakers\, and entrepreneurs seeking to understand and engage with Spain’s evolving deep-tech financing landscape.\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:d1aed8c6d50664dd68d65d25162f3ce6 URL:http://biospain2025.sched.com/event/d1aed8c6d50664dd68d65d25162f3ce6 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T101500Z DTEND:20260930T110000Z SUMMARY:New Approach Methodologies (NAMs): Accelerating Safer\, Smarter and More Human-Relevant Innovation in Drug and Chemical Development DESCRIPTION:New Approach Methodologies (NAMs) are transforming the way drugs\, medical products\, and chemicals are evaluated by providing more predictive\, human-relevant\, and sustainable alternatives to traditional testing approaches. By integrating advanced in vitro models\, computational tools\, artificial intelligence\, in silico toxicology\, and innovative preclinical strategies\, NAMs offer new opportunities to improve safety assessment\, reduce development timelines\, lower costs\, and support regulatory decision-making.\n This round table will bring together leading experts from industry and technology providers to explore the current state and future potential of NAMs across the life sciences sector. The discussion will examine how emerging methodologies are being implemented in research and development workflows\, the scientific and regulatory challenges that remain\, and the collaborative efforts needed to accelerate adoption.\n Representatives from CMG MedDev\, ProtoQSAR\, Labcorp and IVT \;Becytes will share their perspectives on the role of digital technologies\, predictive modeling\, advanced biological systems\, and regulatory science in shaping the next generation of safety and efficacy assessment.\n The session will address key questions including:\n How can NAMs improve the predictivity and translational value of preclinical testing? What role do AI\, computational toxicology\, and in silico approaches play in modern risk assessment? How are regulators responding to the growing adoption of NAMs? What barriers are limiting broader implementation\, and how can they be overcome? How can collaboration between biotechnology companies\, technology developers\, regulators\, and investors accelerate the transition toward human-relevant innovation? Attendees will gain practical insights into the opportunities and challenges associated with NAMs\, as well as a forward-looking view of how these technologies are reshaping drug development\, chemical safety assessment\, and the broader bioeconomy.\n\n\nArosa I+D TBA\nKent Grindstaff\, Consulting Director of Scientific Affairs (Kansas\, USA)\, \;BeCytes Biotechnologies (BioIVT)\, \;TBC\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:0a96856e36e92b7a7355331910863066 URL:http://biospain2025.sched.com/event/0a96856e36e92b7a7355331910863066 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T110000Z DTEND:20260930T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:3571f615929499905aa4adbba9f03a39 URL:http://biospain2025.sched.com/event/3571f615929499905aa4adbba9f03a39 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T110000Z DTEND:20260930T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:91e55b09f032f4a1507452b80f1dc80a URL:http://biospain2025.sched.com/event/91e55b09f032f4a1507452b80f1dc80a END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T110000Z DTEND:20260930T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:99c2d8adaadc903fe4fd8c9ae661811b URL:http://biospain2025.sched.com/event/99c2d8adaadc903fe4fd8c9ae661811b END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T110000Z DTEND:20260930T123000Z SUMMARY:Lunch Break DESCRIPTION:\n CATEGORIES: LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:fe15c37896c80014b89cd2e37010fff2 URL:http://biospain2025.sched.com/event/fe15c37896c80014b89cd2e37010fff2 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T123000Z DTEND:20260930T131500Z SUMMARY:Accelerating Oncology Innovation: Collaborative Models for Early Translation DESCRIPTION:The successful translation of early-stage oncology research into therapies that reach patients requires more than scientific excellence. It demands effective collaboration among researchers\, technology transfer professionals\, biotech companies\, patient organizations\, investors\, and funding institutions. As Europe increasingly embraces collaborative and impact-driven innovation models\, new approaches are emerging to bridge the gap between discovery and clinical application.\n\nThis roundtable will explore how structured collaboration can accelerate oncology innovation and improve the likelihood that promising discoveries reach patients. Using real-world examples from the oncology innovation ecosystem\, the session will highlight how coordinated support mechanisms can de-risk early-stage projects\, strengthen translational pathways\, and ensure patient needs are integrated from the outset.\nThe discussion will address key drivers transforming oncology drug development\, including:\nAdvances in molecular biology\, genomics\, and biomarker-driven clinical development that are enabling more precise and targeted therapeutic strategies.The growing use of real-world data (RWD) and real-world evidence (RWE) to inform clinical development and decision-making.The integration of patient perspectives from the earliest stages of research\, ensuring that scientific priorities\, development pathways\, and innovation outcomes reflect real clinical needs and patient experiences.The application of artificial intelligence and machine learning across the R&D continuum\, from target identification and drug discovery to biomarker development\, clinical trial optimization\, patient recruitment\, and prediction of treatment response and toxicity.Bringing together perspectives from academia\, venture capital\, biotech SMEs\, patient advocacy organizations\, and innovation support entities\, the session will provide actionable insights into how collaborative ecosystems can accelerate oncology innovation and create greater translational impact.\n\nA particular focus will be placed on the role of innovation support and incubation programs in identifying high-potential research projects and transforming them into investable opportunities. Speakers will discuss how early definition of an investment thesis—grounded in patient benefit\, societal impact\, and commercial potential—can strengthen project development and attract follow-on investment. The session will also explore how venture capital investors increasingly contribute beyond financing\, actively supporting project evaluation\, strategic positioning\, and market alignment from the earliest stages. AECC\, the Spanish Association Against Cancer\, will present their pioneering Patient Advocacy programme its complemnetarity to their \; newTechnology Transfer Program.\n\n Representatives from Oncomatryx\, Naru Intelligence\, and Hawk Biosystems will share their experiences in developing cutting-edge technologies\, including antibody-drug conjugates (ADCs)\, AI-driven clinical research solutions\, and next-generation spatial proteomics platforms.\n\nBy showcasing successful examples of cross-sector collaboration\, this session will demonstrate how coordinated innovation ecosystems can accelerate the journey from laboratory discovery to patient benefit.\nParticipants will gain practical insights into building investable\, patient-centered oncology projects and fostering partnerships that accelerate translation and market adoption.\n\n\nProposed Panelists\nRepresentative\, AECC Patient Advocacy Program / AECC INNOVA or AECC IMPACTO initiatives?\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:41fb3dd9b8c9e684dc1c8eb5b26880d6 URL:http://biospain2025.sched.com/event/41fb3dd9b8c9e684dc1c8eb5b26880d6 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T123000Z DTEND:20260930T131500Z SUMMARY:Advancing Transplant Innovation: Bridging Clinical Excellence with Smarter Drug Development DESCRIPTION:A silent storm is sweeping the globe: chronic kidney failure touches more than 850 million lives\, ranks ninth among causes of death\, and affects roughly 10% of the world’s population. In Spain alone\, 15% of adults live with chronic kidney disease and about 68\,000 people require dialysis or transplant to survive. Spain stands out as a beacon of transplant medicine — performing more than 6\,000 kidney transplants a year and consistently leading the world in donor rates and clinical outcomes. Yet even a success story must evolve. To truly conquer organ shortages\, extend long-term graft survival\, and free patients from lifelong immunosuppression\, bold innovation is essential. The horizon is already changing: xenotransplantation\, advanced machine perfusion for organ preservation\, robotic-assisted surgery (an area where Spain is a trailblazer)\, and AI-driven donor–recipient matching are reshaping what’s possible. Transplantation is re-emerging as a frontier of therapeutic invention\, offering a rare opportunity to recast how drugs and biologics are developed for complex\, high-stakes indications. Spain’s dense\, high-volume clinical landscape offers an exceptional proving ground to accelerate next-generation drug development. By weaving together model-informed drug development\, adaptive and innovative trial designs\, and early regulatory alignment\, we can shorten timelines\, reduce development risk\, and create more efficient clinical programs. The complexity of transplant studies — patient heterogeneity\, long timelines\, and shifting endpoints — demands this kind of nimble\, collaborative approach. What’s needed now is stronger partnership between clinical centers\, industry\, regulators\, and patient organizations to build an integrated ecosystem for transplant-focused innovation. The upcoming round table will explore how Spain can leverage its clinical excellence to become a global reference for transplant drug development\, and how a forward-looking\, coordinated strategy can turn today’s promise into tomorrow’s cures. CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:d895151417f1da86adc2f1e6ca432634 URL:http://biospain2025.sched.com/event/d895151417f1da86adc2f1e6ca432634 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T123000Z DTEND:20260930T131500Z SUMMARY:Unlocking Opportunities in precision fermentation for the food industry DESCRIPTION:Imagine a kitchen where tiny\, tireless chefs—yeast\, bacteria\, or fungi—are taught new recipes at the molecular level. That is precision fermentation: a carefully controlled\, biology-driven process that programs microorganisms to churn out specific food ingredients\, from enzymes and flavor molecules to structurally complex proteins. Using modern genetic and metabolic engineering\, these microbial artisans produce high-purity molecules that once came only from animals or cumbersome extraction processes\, offering a platform that’s predictable\, scalable\, and potentially kinder to the planet. \n\n One of the clearest and most evocative examples of this approach is the creation of recombinant caseins. Caseins—the alpha\, beta and kappa family members that give milk its character—are the architect proteins that assemble into micelles\, creating milk’s texture\, emulsifying power\, and its ability to be turned into curds for cheese. \n\n That said\, the path from fermenter to supermarket shelf has practical hurdles: regulatory approval pathways\, production economics\, downstream processing and quality control\, supply-chain integration\, and consumer acceptance all matter. Overcoming these requires engineering\, rigorous testing\, smart economics\, and clear communication about safety and benefits.\n\nPotential speakers\n\nLEVPROT: Sabemos que están trabajando en temas de proteínas dulces por fermentación de precisiónNOVONESIS: Creemos que es una empresa muy potente que puede tener tirón.CocoonAZTI??\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:06898f4c020b2f9b50b69093da431156 URL:http://biospain2025.sched.com/event/06898f4c020b2f9b50b69093da431156 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T131500Z DTEND:20260930T140000Z SUMMARY:Circularity at Scale: The 2030 Value Chain Challenge DESCRIPTION:The European Union has positioned the bioeconomy as a cornerstone of its competitiveness\, sustainability\, and strategic autonomy agenda. The recently launched Strategy for a Competitive and Sustainable EU Bioeconomy seeks to accelerate the transition from innovation to industrial deployment by removing regulatory barriers\, scaling investment\, creating lead markets for bio-based solutions\, and strengthening sustainable biomass value chains.\n \nThis roundtable will explore how Europe's new policy framework can translate into growth opportunities for biotechnology companies\, investors\, industrial partners\, and regional innovation ecosystems. Discussions will focus on the practical implications of the strategy's four pillars: accelerating innovation and scale-up\, developing markets for bio-based products and technologies\, securing sustainable feedstocks and circular value chains\, and strengthening Europe's global leadership in the bioeconomy. \n\nBringing together representatives from industry\, policymakers\, investors\, and innovation organizations\, the session will examine the actions needed to move bio-based innovations from the laboratory to commercial deployment. Particular attention will be given to regulatory modernization\, industrial financing\, public procurement\, advanced biomanufacturing\, and the creation of demand for sustainable bio-based solutions.\n\nAs Europe seeks to build resilient value chains and reduce dependence on fossil-based resources\, this discussion will highlight how biotechnology can become a key driver of industrial transformation\, economic growth\, and environmental sustainability across the continent. \n\nKey discussion questions:\nHow can Europe accelerate the scale-up and commercialization of bio-based innovations?What regulatory and financing mechanisms are needed to strengthen industrial biotechnology competitiveness?How can lead markets be created for bio-based materials\, chemicals\, food ingredients\, and advanced biomanufacturing solutions?What role should public procurement and industrial partnerships play in driving demand?How can Europe strengthen its strategic autonomy while ensuring sustainable and circular biomass value chains? This framing aligns much more closely with the European Commission's 2025 Bioeconomy Strategy and AseBio's advocacy around regulatory streamlining\, industrial scale-up\, investment mobilization\, and market creation. \n\nYa he contactado con estos y estos pendiente de su contestación\, excepto ASINCAR que ya ha dado el ok.\nCelignis\, Irlanda\, SME\, AgrifoodASINCAR\, España\, RTO\, Agrifood à CONFIRMADOSDecathlon\, Francia\, Industria\, TextilNovamont\, Italia\, Industria\, BioplasticosNido\, España\, Start-up\, Materiales biobasados\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:86086b6e5873f11713315ba861411bd9 URL:http://biospain2025.sched.com/event/86086b6e5873f11713315ba861411bd9 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T131500Z DTEND:20260930T140000Z SUMMARY:Current innovation trends in therapeutic technologies and modalities: what is the potential of Spain to ride these waves? DESCRIPTION:A guided tour of Spain’s biomedical frontier: where tomorrow’s therapies are being born\, who’s driving them\, which technologies enable them\, and how to convert those breakthroughs into investment and company-building opportunities CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:1efa2fa05ed97fce3a739a20d2fb0fe5 URL:http://biospain2025.sched.com/event/1efa2fa05ed97fce3a739a20d2fb0fe5 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T131500Z DTEND:20260930T140000Z SUMMARY:Substance Matters: From Microbiome Breakthroughs to EU Benchmarks DESCRIPTION:Human-derived substances are at the forefront of a new wave of biomedical innovation\, spanning cell therapies\, microbiome-based interventions\, and advanced medicinal products. As these technologies rapidly evolve\, so too does the complexity of the regulatory landscape governing their development and clinical application within the European Union.\n This session will explore the scientific\, clinical\, and regulatory dimensions of substances of human origin (SoHO)\, with a focus on how emerging frameworks aim to balance patient safety\, ethical considerations\, and innovation. Experts will provide insights into the latest EU regulatory developments\, including classification challenges\, compliance pathways\, and the implications of the evolving SoHO regulation.\n A featured perspective from industry will highlight real-world translation\, showcasing how cutting-edge companies—such as those working in microbiome therapeutics—navigate regulatory uncertainty while advancing novel therapies toward the clinic. The discussion will emphasize practical strategies for stakeholders across biotech\, healthcare\, and policy to effectively bring human-derived innovations to market.\n Join us to unpack what truly constitutes “substance” in today’s biotech ecosystem—and how Europe is shaping its future.\n\nMicroviable\n¿CSL?\n¿Arosa I+D?\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:7f185ef3e38bfbd3e45f09be241b3789 URL:http://biospain2025.sched.com/event/7f185ef3e38bfbd3e45f09be241b3789 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T131500Z DTEND:20260930T143000Z SUMMARY:Startup Pitch Presentations. Drug Development & Delivery DESCRIPTION:Each company will be given a six-minute spotlight to unveil investment opportunities in drug development and delivery—six minutes to ignite interest and sketch the future of medicine.\n\nAttendees will be invited to vote for the best start up pitch presentation. The winner will get a free registration to BIOSPAIN 2027.\n\nVaxdyn \;– \;Juan José Infante Viñolo\, CEO\nFatrixGel \; – Pablo Sánchez-Rey Chiapasco\, CEO & FounderFlavii Therapeutics \; \;– \;Ariadna Boloix Amenós & Ainia Bellver \;\, \;CEO & CSO & Co-foundersGate2brain \;– \;Mertixell Teixidó Turà\, CEO & CSOi+Med S.coop \;– \; \;Andrea Zapater Matute\, \;R&D Business DeveloperMolefy Pharma - Tania Ortuño\, Head of OperationsNanogrow Biotech \;– \;Nicolás Galmarini Galmarini\, \;CEO & Co-founderNostrum Biodiscovery \;–Marie-Eve Beaulieu\, General ManagerOlavide Neuron STX S.L. (ONESTX) \;– Ángel Cebolla Ramírez\, CEOPloid AI Biotech - Adolfo Gastalver\, Co-Founder & CEOResistia \;– \;Ignacio Massone\, \;CEO & Co-founder\n CATEGORIES:STARTUP PITCH PRESENTATIONS LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:25a8c69cbaee877e79daa1aa523f86e0 URL:http://biospain2025.sched.com/event/25a8c69cbaee877e79daa1aa523f86e0 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T140000Z DTEND:20260930T144500Z SUMMARY:Advances in Neurodegenerative Diseases: From Novel Therapies to Real-World Clinical Validation DESCRIPTION:Neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS)\, Multiple Sclerosis (MS)\, and Alzheimer's Disease continue to pose major scientific\, clinical\, and societal challenges. At the same time\, unprecedented advances in molecular biology\, drug discovery\, biomarkers\, precision medicine\, and advanced therapeutic approaches are transforming the landscape of neurological research and care.\n\nThis round table will bring together leading experts from academia\, biotechnology\, and clinical practice to discuss the latest innovations driving the development of next-generation therapies for neurodegenerative disorders. The discussion will explore emerging therapeutic strategies\, including novel small molecules\, biologics\, regenerative and gene-based approaches\, as well as the critical role of translational research in accelerating their path to patients.\nParticipants will examine how cutting-edge discoveries are being validated through clinical studies and real-world evidence\, addressing key challenges related to efficacy assessment\, biomarker development\, patient stratification\, regulatory pathways\, and long-term outcomes. Particular attention will be given to lessons learned across ALS\, MS\, and Alzheimer's disease\, highlighting opportunities for cross-disciplinary collaboration and innovation.\n\nFeaturing insights from Adolfo López de Munain\, representatives of Golden Gait Biotech and CIC bioGUNE\, and Ana Martínez Gil\, the session will provide a comprehensive perspective on how scientific breakthroughs are advancing from the laboratory to clinical validation and\, ultimately\, to improved patient outcomes.\n\nKey themes:\nAdvanced therapeutic approaches for ALS\, MS\, and Alzheimer's diseaseTranslational pathways from discovery to clinical applicationBiomarkers and patient stratification for precision neurologyClinical trial innovation and real-world evidence generationCollaboration between academia\, healthcare systems\, and biotech companiesFuture opportunities and challenges in neurodegenerative disease treatment developmentThis discussion will offer attendees a unique opportunity to gain insights into the evolving neurodegenerative disease ecosystem and the strategies shaping the next generation of therapeutic innovation.\n\nSpeakersMónica Povedano\, Hospital Univ. Bellvitge\, Neurology Service\, TBC\nQuimatryx\, TBA\nBMS? CATEGORIES:ROUND TABLE DISCUSSION LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:0a9bce41a55af807bf7f5d12feb4bde2 URL:http://biospain2025.sched.com/event/0a9bce41a55af807bf7f5d12feb4bde2 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T140000Z DTEND:20260930T144500Z SUMMARY:One Health Diagnostics: Rapid Detection and Characterization of Multidrug Resistant Bacteria to Enable Next Generation Antimicrobials DESCRIPTION:Imagine a crossroads where human health\, animal welfare\, and the environment meet — and a new generation of sentinels stands guard. This panel will convene those sentinels to tackle the urgent challenge of protecting vulnerable people and animals from disease driven by major antibiotic‑resistant threats\, and to showcase the bleeding‑edge tools that spot and dissect multidrug‑resistant bacteria across clinical\, food and environmental landscapes within a One Health framework. We’ll voyage through the knotted realities of vaccine development and market access\, then move into the fast‑moving world of diagnostics: gene‑based LAMP assays that turn hours into minutes\, electrochemical biosensors that read microbial whispers as electrical signals\, nanomaterial‑amplified methods that reveal the faintest traces of pathogens\, microfluidic “lab on a chip” platforms that miniaturize whole laboratories\, and point‑of‑care systems built for real‑world decisions. The growing appreciation for vaccines—from immune surrogates of protection to fresh insights into host‑pathogen dynamics and sharper disease definitions—will be explored as a keystone for prevention. Recent breakthroughs already sound like science fiction: sub‑hour detection of key AMR genes\, ultra‑low limits of detection in messy samples\, and real‑time antimicrobial susceptibility testing that brings clinical and research timelines into alignment. These advances not only sharpen bedside decision making but also feed drug discovery with high‑resolution pathogen profiles that accelerate new antimicrobial development. The panel will bring together thought leaders in vaccines\, diagnostics\, microfluidics\, biosensing\, environmental microbiology\, and pharmaceutical innovation to chart the next frontiers in AMR detection — and to imagine how those frontiers will reshape the hunt for tomorrow’s drugs.\n\n\nIntroduction – The One Health Challenge of MDR Bacteria (5 min)\nBlock 1 - From Immunity to Impact: Building Executable AMR Vaccines (15 min)\nBlock 2 – Genetic Detection of MDR Bacteria: LAMP and Other Rapid Molecular Techniques (15 min)\nBlock 3 – Electrochemical Biosensing: Fast\, Sensitive Characterization of MDR Bacteria (15 min)\nBlock 4 – Point of Care Devices and Lab on a Chip Systems for Rapid AMR Decision-Making (15 min)\nBlock 5 – Connecting Diagnostics to Drug Development: The Feedback Loop (10 min)\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:2efaad74bdcc538e1a0e0a5e116530e8 URL:http://biospain2025.sched.com/event/2efaad74bdcc538e1a0e0a5e116530e8 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20260930T144500Z DTEND:20260930T153000Z SUMMARY:From Biotechnology to Clinical Intelligence: How to Build Biotech Solutions Powered by Software and AI\, Interoperable by Design in Europe. Practical case: use in histopathology for biomarker identification DESCRIPTION:The integration of biotechnology\, software\, and artificial intelligence is redefining the development of advanced solutions for diagnosis\, patient stratifica on\, and precision medicine. However\, the effective transla on of these innovations into the European clinical environment requires going beyond analytical performance or the experimental validation of biomarkers. It also requires the ability to design robust\, interoperable\, and regulatorily aligned systems capable of integrating into complex and highly standardized healthcare ecosystems. \n\n This round table will examine how to build biotech solutions powered by soware and AI under an interoperability-by-design approach\, incorporating from the earliest stages aspects such as data architecture\, semantic standardization\, traceability\, algorithmic governance\, and regulatory compliance. In the European context\, frameworks such as the European Health Data Space (EHDS)\, the AI Act\, and the regulations applicable to medical devices and in vitro diagnostics (MDR/IVDR) are shaping a new paradigm in which evidence generation\, data quality\, and the capacity for technical and semantic integra on are inseparable from clinical value and market viability. \n\n As a practical case\, the presentation will address the use of AI in digital histopathology for biomarker iden fica on\, an area of par cular relevance due to its poten al in precision oncology and its high methodological complexity. The combina on of digital imaging\, computational analysis\, and correla on with molecular and clinical data makes it possible to move toward more reproducible and scalable models of ssue characteriza on. However\, its effective implementation depends on the harmonization of formats\, pre-analytical and analytical quality\, clinical validation\, and interoperability with pathology systems\, electronic health records\, and biomedical data platforms. Innovation in AI-based biotechnology cannot be understood solely as an algorithmic challenge. Interoperability is no longer an IT project\; it is strategic infrastructure for enabling European biotech to scale with AI.\n\nAEMPS??? CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:7029b932ebb8e0f97466def331baf818 URL:http://biospain2025.sched.com/event/7029b932ebb8e0f97466def331baf818 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T073000Z DTEND:20261001T081500Z SUMMARY:From Lab Coats to Suits: Essential Roles in the Biotech Journey DESCRIPTION:· \;Moderación: Persona de LIM Global\n· \;Ponentes:\no \;Perfil I+D: David Álvarez Ordás (Roche)\no \;Perfil Manufacturing / Operations: Persona de 3P BIOVAN\no \;Perfil Regulatory Affairs: Persona de Viralgen\no \;Perfil Marketing: Persona de HIPRA\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:7de1e021deacf08bf78e6984614299ba URL:http://biospain2025.sched.com/event/7de1e021deacf08bf78e6984614299ba END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T081500Z DTEND:20261001T090000Z SUMMARY:Magnetize & Maintain: Speeding up attraction\, securing long-term retention DESCRIPTION:Mesa redonda 2: “Magnetize & Maintain: Speeding up attraction\, securing long-term retention”\n· \;Moderación: Persona de FEBiotec\n· \;Ponentes:\no \;Perfil consultoría HR: Persona de LIM Global\no \;Perfil STEM: Persona de Bizkaia Talent\no \;Perfil formación: Persona de CESIF\no \;Perfil HR en empresa biotec: Paola Salanueva (Histocell)\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:d599d0dfc8291f0c4c22cd53a4c7d1cc URL:http://biospain2025.sched.com/event/d599d0dfc8291f0c4c22cd53a4c7d1cc END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T090000Z DTEND:20261001T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:2 Dorotea Barnés room\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:056175321939145bede1a32bbaf5bc11 URL:http://biospain2025.sched.com/event/056175321939145bede1a32bbaf5bc11 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T090000Z DTEND:20261001T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:3 Nicolás Achúcarro room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:32b8b7f6fc1745daecd933ed16327313 URL:http://biospain2025.sched.com/event/32b8b7f6fc1745daecd933ed16327313 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T090000Z DTEND:20261001T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:4 Raúl Martín room\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:6c9dc444dfae5b2006ff74362832fc05 URL:http://biospain2025.sched.com/event/6c9dc444dfae5b2006ff74362832fc05 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T090000Z DTEND:20261001T093000Z SUMMARY:Coffee break DESCRIPTION:\n CATEGORIES: LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:92506a6e34a4beb743bd0fdd3ea37d4b URL:http://biospain2025.sched.com/event/92506a6e34a4beb743bd0fdd3ea37d4b END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T093000Z DTEND:20261001T101500Z SUMMARY:Unlocking the Lab: Navigating Patents and the Spin-off Landscape DESCRIPTION:· \;Moderación: Persona de FEBiotec\n· \;Ponentes:\no \;Perfil patentes: Persona de Manuel Illescas\no \;Perfil inversor: Persona de Ysios Capital\n\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:7f9fa945ddf6d7c035e7f8015dab2ce3 URL:http://biospain2025.sched.com/event/7f9fa945ddf6d7c035e7f8015dab2ce3 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T101500Z DTEND:20261001T110000Z SUMMARY:Decoding the Future: AI and the Digital Transformation of Biotech DESCRIPTION:Moderación: Persona de una spin-off no elegida como ponenteo \;Perfil spin-off: BioComputing o HAWK Biosystems / Ubikare\no \;Perfil automatización: Persona de Agilent technologies\no \;Perfil uso IA para búsqueda fármacos: Persona de MSD\no \;Perfil uso IA en CDMO: Persona de Klinea\n\n CATEGORIES:ROUND TABLE DISCUSSION LOCATION:1 Margarita Salas auditorium\, Azkue Kalea\, 1\, 48902 San Vicente de Barakaldo\, Bizkaia SEQUENCE:0 UID:a5d0195a41115ce1838cbc451d7a6d85 URL:http://biospain2025.sched.com/event/a5d0195a41115ce1838cbc451d7a6d85 END:VEVENT BEGIN:VEVENT DTSTAMP:20260706T112527Z DTSTART:20261001T103000Z DTEND:20261001T110000Z SUMMARY:Passing the baton to Barcelona DESCRIPTION:With warm thanks to our regional hosts — the Provincial Government of Bizkaia and the Government of the Basque Country — we’re delighted to hand the baton to our friends from Catalonia\, who will host the next edition of BIOSPAIN. See you in Barcelona for BIOSPAIN 2027! CATEGORIES:CEREMONY LOCATION:Biocat Booth #45\, Azkue Kalea\, 1\, 48903 San Vicente de Barakaldo\, Bizkaia\, Spain SEQUENCE:0 UID:bb09a06f0426dc468e223b560a958dd6 URL:http://biospain2025.sched.com/event/bb09a06f0426dc468e223b560a958dd6 END:VEVENT END:VCALENDAR